The alpha thalassemia market is expected to expand significantly by 2036, driven by rising prevalence and innovations in diagnostics and gene therapies. Companies like Agios Pharmaceuticals and Novo Nordisk are leading clinical trials for new treatments such as PYRUKYND and etavopivat, which aim to reduce transfusion dependency. While no gene therapies are yet approved, regulatory reviews are underway, and advancements in genetic testing are improving early diagnosis and patient management. This growth reflects unmet needs and increasing awareness in major regions including the US, EU4, UK, and Japan.
The European Commission has approved Novo Nordisk's Wegovy pill, the first oral GLP-1 receptor agonist for weight management across the EU. This approval covers adults with obesity or overweight with related health issues and follows positive clinica...
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
